Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,726.13
(
0.30%
)
News Focus
News Focus

Replies to post #10717 on Momenta Pharmaceuticals, Inc. (MNTA)

Replies to #10717 on Momenta Pharmaceuticals, Inc. (MNTA)
icon url

DewDiligence

07/26/13 11:32 AM

#10718 RE: rajaram46 #10717

It means Teva's 2015 process patent is unenforceable and hence MNTA/NVS (and MYL) can launch generic Copaxone in May 2014, pending FDA approval.